博安生物-B(06955.HK)預計12月30日上市 引入中國生物製藥等基石
格隆匯12月19日丨博安生物-B(06955.HK)發佈公吿，公司擬全球發售1069.48萬股股份，其中中國香港發售股份106.96萬股，國際發售股份962.52萬股，另有15%超額配股權；2022年12月19日至12月22日招股；發售價為每股發售股份19.80港元，每手買賣單位200股，入場費約3999.9港元；瑞銀集團及安信國際為聯席保薦人；預期股份將於2022年12月30日於聯交所主板掛牌上市。
集團於2013年成立，是一家綜合性生物製藥公司，致力於在中國及海外開發、製造及商業化不同治療領域的優質生物製品。生物製品的主要類型包括抗體、融合蛋白、ADC、重組蛋白、疫苗、基因療法及細胞療法。生物類似藥為與現有經批准參照藥高度相似但在臨牀上並無重大差異的生物製品。創新抗體藥物為在全球或中國並未獲批准的生物製品。集團的平台、員工及合作伙伴關係專注於提供生物類似藥及創新生物製品。
集團已訂立基石投資協議，據此，基石投資者已同意在若干條件規限下，按發售價認購有關數目的發售股份，購買總額約為1.504億港元。基於發售價19.8港元計算，基石投資者將認購的發售股份總數將為759.4萬股，佔根據全球發售提呈發售的發售股份約71.01%，以及佔緊隨全球發售完成後已發行H股及已發行股本總額約1.49%(假設超額配股權未獲行使)。基石投資者包括傅和亮(為艾迪藥業(688488.SH)的創辦人、董事長、總經理兼首席執行官)、Harvest、中國生物製藥(01177.HK)。
基於發售價每股19.8港元計算及並無計及超額配股權，集團估計將收取全球發售所得款項淨額約1.528億港元。集團目前擬應用該等所得款項淨額約59.5%用於核心產品的研發；約31.4%將用於集團管線中其他產品的研發；約6.1%將用於商業化目的；及約3.0%將用於營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
